Form 4: INSMED Director Sells $4.1M in Stock

INSMED Director Melvin Sharoky sold 20,000 shares of common stock for approximately $4.1 million under a pre-arranged trading plan.

Summary

• Melvin Sharoky, M.D., a Director of INSMED Inc. (INSM), reported the sale of 20,000 shares of common stock.
• The transaction occurred on December 5, 2025, and was executed pursuant to a Rule 10b5-1(c) trading plan.
• The shares were sold at a weighted average price of $205.01 per share, with prices ranging from $205.00 to $205.09.
• The total value of the shares sold amounts to approximately $4,100,200.
• Following this transaction, Dr. Sharoky directly beneficially owns 243,948 shares of INSMED common stock.
• Indirect beneficial ownership includes 0 shares through Baby Gator LLC (after a pro rata distribution of all its shares to members), 5,000 shares through Padonia, LLC (after a pro rata distribution of 5,000 shares to members), 6,847 shares by spouse, and shares held as custodian for several UTMA/FL accounts totaling 13,401 shares (Nolan M. Wink: 5,180; Tulia L. Sharoky: 3,481; Adler J. Wink: 576; Sophie C. Wink: 4,764).

Sentiment

Score: 5

Explanation: The transaction is a pre-arranged sale under a Rule 10b5-1 plan, indicating it was scheduled in advance and not necessarily a reaction to new information. This typically results in a neutral sentiment as it's a personal financial management event rather than a signal about company performance.

Future Outlook

NA

Industry Context

This filing reports a routine insider transaction (stock sale) by a director, which is a common occurrence in publicly traded companies. It does not provide information directly related to broader industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: The sale by a director could be noted by investors, but given it's a pre-arranged 10b5-1 plan, it is generally not interpreted as a negative signal regarding the company's future prospects. The impact is likely minimal.

Key Dates

Keywords

INSMED, INSM, Form 4, Insider Transaction, Stock Sale, Director, Beneficial Ownership, Rule 10b5-1